Important News & Announcements

Stay up to date with the latest news and announcements from NASCSA.

Back to all news

DEA Serves Order to Show Cause on Truepill Pharmacy for its Involvement in the Unlawful Dispensing of Prescription Stimulants

Posted 12/15/2022

December 15, 2022 - Today, DEA served an Order to Show Cause on Truepill, a retail pharmacy that is alleged to have wrongfully filled thousands of prescriptions for stimulants used in the treatment of Attention Deficit/Hyperactivity Disorder (ADHD). Truepill was the pharmacy for telehealth companies, including Cerebral, that marketed ADHD treatments, including Adderall ? and its generic forms, directly to consumers using Internet advertisements and social media. Cerebral arranged for patients to receive prescriptions for ADHD treatments through a telehealth visit, and for Truepill to fill those prescriptions.

?DEA will relentlessly pursue companies and pharmacies that seek to profit from unlawfully dispensing powerful and addictive controlled substances at the expense of the safety and health of the American people,? said DEA Administrator Anne Milgram. ?The men and women of the DEA remain committed to ensuring that every American can access essential medicines when they are lawfully prescribed and dispensed.?

According to the Order to Show Cause, between September 2020 and September 2022, Truepill filled more than 72,000 controlled substance prescriptions, 60 percent of which were for stimulants, including generic forms of Adderall?. In numerous instances, Truepill dispensed controlled substances pursuant to prescriptions that were not issued for a legitimate medical purpose in the usual course of professional practice. An investigation into Truepill?s operations revealed that the pharmacy filled prescriptions that were: unlawful by exceeding the 90-day supply limits; and/or written by prescribers who did not possess the proper state licensing.

An Order to Show Cause is an administrative action to determine whether a DEA Certificate of Registration should be revoked. Until a determination is made, this action does not affect a registrant?s ability to handle or distribute a controlled substance.

Back to all news

Sponsor Spotlight

IQVIA Compliance Solutions

Operational and regulatory resources for navigating the regulatory landscape with confidence

The IQVIA Difference

IQVIA has been an industry expert in DEA and state operational compliance and a leading provider of regulatory services since 1991. Our long-standing compliance solutions support the industry and the health care community in the areas of the Controlled Substance Act, Prescription Drug Marketing Act and more specifically, state pharmacy and wholesale distribution regulatory issues, as well as operational best practices.

Staffed by former DEA investigators, policy makers and industry experts, IQVIA offers comprehensive solutions to support Registrants at any stage of the journey to achieve regulatory compliance. Our expert services also include:

  • Unparalleled experience developing SOM solutions
  • State services for licensing assistance and other requirements
  • Proactively monitor the regulatory and enforcement landscapes
  • Bridge the gap between regulation and practice

www.iqvia.com

All Sponsors